tetano
Editor, Senior Moderator
Arch Virol. 2013 Dec 1. [Epub ahead of print]
A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus.
Fonseca W, Ozawa M, Hatta M, Orozco E, Mart?nez MB, Kawaoka Y.
Source
Departamento de Infect?mica y Patog?nesis Molecular, Centro de Investigaci?n y de Estudios Avanzados, Instituto Polit?cnico Nacional, Mexico, Mexico.
Abstract
Infections with influenza and respiratory syncytial virus (RSV) rank high among the most common human respiratory diseases worldwide. Previously, we developed a replication-incompetent influenza virus by replacing the coding sequence of the PB2 gene, which encodes one of the viral RNA polymerase subunits, with that of a reporter gene. Here, we generated a PB2-knockout recombinant influenza virus expressing the F protein of RSV (PB2-RSVF virus) and tested its potential as a bivalent vaccine. In mice intranasally immunized with the PB2-RSVF virus, we detected high levels of antibodies against influenza virus, but not RSV. PB2-RSVF virus-immunized mice were protected from a lethal challenge with influenza virus but experienced severe body weight loss when challenged with RSV, indicating that PB2-RSVF vaccination enhanced RSV-associated disease. These results highlight one of the difficulties of developing an effective bivalent vaccine against influenza virus and RSV infections.
PMID:
24292020
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24292020
A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus.
Fonseca W, Ozawa M, Hatta M, Orozco E, Mart?nez MB, Kawaoka Y.
Source
Departamento de Infect?mica y Patog?nesis Molecular, Centro de Investigaci?n y de Estudios Avanzados, Instituto Polit?cnico Nacional, Mexico, Mexico.
Abstract
Infections with influenza and respiratory syncytial virus (RSV) rank high among the most common human respiratory diseases worldwide. Previously, we developed a replication-incompetent influenza virus by replacing the coding sequence of the PB2 gene, which encodes one of the viral RNA polymerase subunits, with that of a reporter gene. Here, we generated a PB2-knockout recombinant influenza virus expressing the F protein of RSV (PB2-RSVF virus) and tested its potential as a bivalent vaccine. In mice intranasally immunized with the PB2-RSVF virus, we detected high levels of antibodies against influenza virus, but not RSV. PB2-RSVF virus-immunized mice were protected from a lethal challenge with influenza virus but experienced severe body weight loss when challenged with RSV, indicating that PB2-RSVF vaccination enhanced RSV-associated disease. These results highlight one of the difficulties of developing an effective bivalent vaccine against influenza virus and RSV infections.
PMID:
24292020
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24292020